{"id":61744,"date":"2025-08-19T13:05:27","date_gmt":"2025-08-19T11:05:27","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/aldeyra-therapeutics-receives-fast-track-designation-for-adx%e2%80%912191-for-the-treatment-of-retinitis-pigmentosa\/"},"modified":"2025-08-19T13:05:27","modified_gmt":"2025-08-19T11:05:27","slug":"aldeyra-therapeutics-receives-fast-track-designation-for-adx%e2%80%912191-for-the-treatment-of-retinitis-pigmentosa","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/aldeyra-therapeutics-receives-fast-track-designation-for-adx%e2%80%912191-for-the-treatment-of-retinitis-pigmentosa\/","title":{"rendered":"Aldeyra Therapeutics Receives Fast Track Designation for ADX\u20112191 for the Treatment of Retinitis Pigmentosa"},"content":{"rendered":"
\n

LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc.<\/a> (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for ADX-2191 (methotrexate intravitreal injection, USP) for the treatment of retinitis pigmentosa. There is currently no approved treatment for patients with most forms of retinitis pigmentosa, a clinical group of rare genetic eye diseases characterized by retinal cell death and loss of vision. Retinitis pigmentosa affects more than one million people worldwide.<\/p>\n

\n\u201cAlthough retinitis pigmentosa is a relentlessly progressive condition that has been recognized for decades as a significant cause of blindness, there are no approved therapies for most forms of the disease,\u201d stated Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra. \u201cFast Track Designation in conjunction with the previously announced Orphan Drug Designation underscores the potential for ADX-2191 to address an unmet need in the field of ophthalmology and creates the framework for ADX-2191, if approved, to reach patients promptly.\u201d<\/p>\n

\nThe potential activity of ADX-2191 in retinitis pigmentosa is supported by results from a Phase 2 clinical trial, announced in 2023, which demonstrated improvements from baseline in retinal sensitivity following treatment. A planned Phase 2\/3 clinical trial of ADX-2191 in retinitis pigmentosa is expected to initiate in 2025.<\/p>\n

\nFast Track Designation is designed to facilitate the development and expedite the review of drugs that are intended to treat serious or life-threatening conditions and that demonstrate the potential to address an unmet medical need. Fast Track Designation enables frequent FDA interactions and may allow for rolling review, priority review, or accelerated approval if relevant criteria are met.<\/p>\n

\nAbout ADX-2191<\/b><\/p>\n

\nADX-2191 (methotrexate injection, USP) is a sterile, non-compounded intravitreal formulation of methotrexate for the potential treatment of specific rare retinal diseases, including primary vitreoretinal lymphoma and retinitis pigmentosa. The ADX-2191 intravitreal formulation is preservative-free, is designed to be vitreous-compatible, and is optimized for excipient composition, viscosity, density, tonicity, pH, concentration, and volume of administration. ADX-2191 has received FDA Orphan Drug Designation for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa, Fast Track Designation for the treatment of retinitis pigmentosa, and EMA Orphan Designation for the treatment of inherited retinal dystrophies of the rod-dominant phenotype, including retinitis pigmentosa, and the treatment of primary large B-Cell lymphomas of immune privileged sites, including primary vitreoretinal lymphoma.<\/p>\n

\nAbout Retinitis Pigmentosa<\/b><\/p>\n

\nRetinitis pigmentosa is a group of rare genetic eye diseases characterized by retinal cell death and loss of vision. There are currently no approved treatments for most forms of retinitis pigmentosa. In vivo preclinical research has identified the activity of methotrexate in inducing misfolded rhodopsin (a visual cycle protein) clearance, suggesting the potential of ADX\u20112191 to treat genetic forms of retinitis pigmentosa that are characterized by misfolded rhodopsin.<\/p>\n

\nAbout Aldeyra<\/b><\/p>\n

\nAldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated and metabolic diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-629, ADX\u2011248, ADX-743, ADX-631, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated and metabolic diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.<\/p>\n

\nSafe Harbor Statement<\/b><\/p>\n

\nThis release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Aldeyra\u2019s future expectations, plans, and prospects, including without limitation statements regarding: the goals, opportunity, and potential for ADX-2191; and the outcome and timing of any clinical trials of ADX-2191. Aldeyra intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terms such as, but not limited to, \u201cmay,\u201d \u201cmight,\u201d \u201cwill,\u201d \u201cobjective,\u201d \u201cintend,\u201d \u201cshould,\u201d “could,” \u201ccan,\u201d \u201cwould,\u201d \u201cexpect,\u201d \u201cbelieve,\u201d \u201canticipate,\u201d \u201cproject,\u201d \u201con track,\u201d \u201cscheduled,\u201d \u201ctarget,\u201d \u201cdesign,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201ccontemplates,\u201d \u201clikely,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201congoing,\u201d \u201caim,\u201d \u201cplan,\u201d or the negative of these terms, and similar expressions intended to identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions, and uncertainties. Aldeyra is at an early stage of development and may not ever have any products that generate significant revenue. All of Aldeyra’s development timelines may be subject to adjustment depending on recruitment rate, regulatory review, preclinical and clinical results, funding, and other factors that could delay the initiation, enrollment, or completion of clinical trials. Important factors that could cause actual results to differ materially from those reflected in Aldeyra’s forward-looking statements include, among others, the timing of enrollment, commencement and completion of Aldeyra’s clinical trials, the timing and success of preclinical studies and clinical trials conducted by Aldeyra and its development partners; delay in or failure to obtain regulatory approval of Aldeyra’s product candidates, including as a result of the FDA not accepting Aldeyra\u2019s regulatory filings, issuing a complete response letter, or requiring additional clinical trials or data prior to review or approval of such filings or in connection with resubmissions of such filings; the ability to maintain regulatory approval of Aldeyra’s product candidates, and the labeling for any approved products; the risk that prior results, such as signals of safety, activity, or durability of effect, observed from preclinical or clinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving Aldeyra’s product candidates in clinical trials focused on the same or different indications; the scope, progress, expansion, and costs of developing and commercializing Aldeyra’s product candidates; uncertainty as to Aldeyra\u2019s ability to commercialize (alone or with others) and obtain reimbursement for Aldeyra’s product candidates following regulatory approval, if any; the size and growth of the potential markets and pricing for Aldeyra’s product candidates and the ability to serve those markets; Aldeyra’s expectations regarding Aldeyra’s expenses and future revenue, the timing of future revenue, the sufficiency or use of Aldeyra’s cash resources and needs for additional financing; the rate and degree of market acceptance of any of Aldeyra’s product candidates; Aldeyra’s expectations regarding competition; Aldeyra’s anticipated growth strategies; Aldeyra’s ability to attract or retain key personnel; Aldeyra\u2019s commercialization, marketing and manufacturing capabilities and strategy; Aldeyra’s ability to establish and maintain development partnerships; Aldeyra\u2019s ability to successfully integrate acquisitions into its business; Aldeyra’s expectations regarding federal, state, and foreign regulatory requirements; political, economic, legal, social, and health risks, public health measures, and war or other military actions, that may affect Aldeyra\u2019s business or the global economy; regulatory developments in the United States and foreign countries; Aldeyra’s ability to obtain and maintain intellectual property protection for its product candidates; the anticipated trends and challenges in Aldeyra’s business and the market in which it operates; and other factors that are described in the \u201cRisk Factors\u201d and \u201cManagement’s Discussion and Analysis of Financial Condition and Results of Operations\u201d sections of Aldeyra’s Annual Report on Form 10-K for the year ended December 31, 2024, and Aldeyra\u2019s Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, which are on file with the Securities and Exchange Commission (SEC) and available on the SEC website at https:\/\/www.sec.gov\/<\/a>. Additional factors may be described in those sections of Aldeyra\u2019s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, expected to be filed with the SEC in the fourth quarter of 2025, and Aldeyra\u2019s other filings with the SEC.<\/p>\n

\nIn addition to the risks described above and in Aldeyra’s other filings with the SEC, other unknown or unpredictable factors also could affect Aldeyra’s results. No forward-looking statements can be guaranteed and actual results may differ materially from such statements. The information in this release is provided only as of the date of this release, and Aldeyra undertakes no obligation to update any forward-looking statements contained in this release on account of new information, future events, or otherwise, except as required by law.<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor & Media Contact:
\n
Laura Nichols
\n
Tel: (781) 257-3060
\n
investorrelations@aldeyra.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for ADX-2191 (methotrexate intravitreal injection, USP) for the treatment of retinitis pigmentosa. There is currently no approved treatment for patients with most forms of retinitis pigmentosa, a clinical group of rare genetic … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61744","6":"format-standard","7":"category-industry"},"yoast_head":"\nAldeyra Therapeutics Receives Fast Track Designation for ADX\u20112191 for the Treatment of Retinitis Pigmentosa - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/aldeyra-therapeutics-receives-fast-track-designation-for-adx\u20112191-for-the-treatment-of-retinitis-pigmentosa\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Aldeyra Therapeutics Receives Fast Track Designation for ADX\u20112191 for the Treatment of Retinitis Pigmentosa - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for ADX-2191 (methotrexate intravitreal injection, USP) for the treatment of retinitis pigmentosa. There is currently no approved treatment for patients with most forms of retinitis pigmentosa, a clinical group of rare genetic ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/aldeyra-therapeutics-receives-fast-track-designation-for-adx\u20112191-for-the-treatment-of-retinitis-pigmentosa\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-19T11:05:27+00:00\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aldeyra-therapeutics-receives-fast-track-designation-for-adx%e2%80%912191-for-the-treatment-of-retinitis-pigmentosa\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aldeyra-therapeutics-receives-fast-track-designation-for-adx%e2%80%912191-for-the-treatment-of-retinitis-pigmentosa\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Aldeyra Therapeutics Receives Fast Track Designation for ADX\u20112191 for the Treatment of Retinitis Pigmentosa\",\"datePublished\":\"2025-08-19T11:05:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aldeyra-therapeutics-receives-fast-track-designation-for-adx%e2%80%912191-for-the-treatment-of-retinitis-pigmentosa\\\/\"},\"wordCount\":1414,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aldeyra-therapeutics-receives-fast-track-designation-for-adx%e2%80%912191-for-the-treatment-of-retinitis-pigmentosa\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aldeyra-therapeutics-receives-fast-track-designation-for-adx%e2%80%912191-for-the-treatment-of-retinitis-pigmentosa\\\/\",\"name\":\"Aldeyra Therapeutics Receives Fast Track Designation for ADX\u20112191 for the Treatment of Retinitis Pigmentosa - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"datePublished\":\"2025-08-19T11:05:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aldeyra-therapeutics-receives-fast-track-designation-for-adx%e2%80%912191-for-the-treatment-of-retinitis-pigmentosa\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aldeyra-therapeutics-receives-fast-track-designation-for-adx%e2%80%912191-for-the-treatment-of-retinitis-pigmentosa\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/aldeyra-therapeutics-receives-fast-track-designation-for-adx%e2%80%912191-for-the-treatment-of-retinitis-pigmentosa\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Aldeyra Therapeutics Receives Fast Track Designation for ADX\u20112191 for the Treatment of Retinitis Pigmentosa\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Aldeyra Therapeutics Receives Fast Track Designation for ADX\u20112191 for the Treatment of Retinitis Pigmentosa - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/aldeyra-therapeutics-receives-fast-track-designation-for-adx\u20112191-for-the-treatment-of-retinitis-pigmentosa\/","og_locale":"en_US","og_type":"article","og_title":"Aldeyra Therapeutics Receives Fast Track Designation for ADX\u20112191 for the Treatment of Retinitis Pigmentosa - Pharma Trend","og_description":"LEXINGTON, Mass.–(BUSINESS WIRE)–Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted fast track designation for ADX-2191 (methotrexate intravitreal injection, USP) for the treatment of retinitis pigmentosa. There is currently no approved treatment for patients with most forms of retinitis pigmentosa, a clinical group of rare genetic ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/aldeyra-therapeutics-receives-fast-track-designation-for-adx\u20112191-for-the-treatment-of-retinitis-pigmentosa\/","og_site_name":"Pharma Trend","article_published_time":"2025-08-19T11:05:27+00:00","author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/aldeyra-therapeutics-receives-fast-track-designation-for-adx%e2%80%912191-for-the-treatment-of-retinitis-pigmentosa\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/aldeyra-therapeutics-receives-fast-track-designation-for-adx%e2%80%912191-for-the-treatment-of-retinitis-pigmentosa\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Aldeyra Therapeutics Receives Fast Track Designation for ADX\u20112191 for the Treatment of Retinitis Pigmentosa","datePublished":"2025-08-19T11:05:27+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/aldeyra-therapeutics-receives-fast-track-designation-for-adx%e2%80%912191-for-the-treatment-of-retinitis-pigmentosa\/"},"wordCount":1414,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/aldeyra-therapeutics-receives-fast-track-designation-for-adx%e2%80%912191-for-the-treatment-of-retinitis-pigmentosa\/","url":"https:\/\/pharma-trend.com\/en\/aldeyra-therapeutics-receives-fast-track-designation-for-adx%e2%80%912191-for-the-treatment-of-retinitis-pigmentosa\/","name":"Aldeyra Therapeutics Receives Fast Track Designation for ADX\u20112191 for the Treatment of Retinitis Pigmentosa - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"datePublished":"2025-08-19T11:05:27+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/aldeyra-therapeutics-receives-fast-track-designation-for-adx%e2%80%912191-for-the-treatment-of-retinitis-pigmentosa\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/aldeyra-therapeutics-receives-fast-track-designation-for-adx%e2%80%912191-for-the-treatment-of-retinitis-pigmentosa\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/aldeyra-therapeutics-receives-fast-track-designation-for-adx%e2%80%912191-for-the-treatment-of-retinitis-pigmentosa\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Aldeyra Therapeutics Receives Fast Track Designation for ADX\u20112191 for the Treatment of Retinitis Pigmentosa"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61744","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61744"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61744\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61744"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61744"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61744"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}